Middle East and Africa Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Middle East and Africa Primary Angle-Closure Glaucoma Market
The primary angle-closure glaucoma market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.2% in the forecast period of 2021 to 2028 and is expected to reach USD 340.82 million by 2028. Increasing prevalence of angle-closure glaucoma and advancement in surgical treatment of the disease are the key drivers for primary angle-closure glaucoma market.
Glaucoma is a group of eye conditions that damage the optic nerve and the proper functioning of the optic nerve is necessary for good vision. This damage is often caused by abnormally high pressure in the eye. The primary angle-closure (PAC) is defined as appositional or synechial closure of the anterior chamber angle which can lead to aqueous outflow obstruction and raised IOP in the absence of glaucomatous optic neuropathy.
The increasing population of women and greater female to male ratio in angle-closure glaucoma due to various anatomical and hormonal factors showed the prevalence of the disease in women with increasing women population which is expected to drive the primary angle-closure glaucoma market in the forecasted period. The poor reimbursements are seen as a restraint for the primary angle-closure glaucoma market. The governing body for the approval of products has a significant role in the primary angle-closure glaucoma market growth. The increasing approval of the product for the primary angle-closure glaucoma is expected to boost the market in the forecasted period and will act as opportunities for the primary angle-closure glaucoma market growth. The risks associated with the micro-invasive glaucoma surgery acts as a challenge for the primary angle-closure glaucoma market.
The primary angle-closure glaucoma market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the primary angle-closure glaucoma market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Primary Angle-Closure Glaucoma Market Scope and Market Size
The primary angle-closure glaucoma market is segmented on the basis of the disease type, type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the primary angle-closure glaucoma market is segmented into acute angle-closure glaucoma and chronic angle-closure glaucoma. In 2021, acute angle-closure glaucoma segment is dominating in the primary angle-closure glaucoma market owing to the high incidence cases for acute cases.
- On the basis of type, the primary angle-closure glaucoma market is segmented into diagnosis and treatment. In 2021, diagnosis segment is dominating in the primary angle-closure glaucoma market due to the primary test and secondary testing options available for the diagnosis and physicians after a proper diagnosis only prefer the medical procedure.
- On the basis of end user, the primary angle-closure glaucoma market is segmented into hospitals, specialty clinics, ambulatory surgical centers and others. In 2021, hospitals segment is dominating the primary angle-closure glaucoma market as this segment is specialized in conducting various surgical interventions and has a large professional’s portfolio available for giving the proper treatment.
- On the basis of distribution channel, the primary angle-closure glaucoma market is segmented into direct tender, retail sales and others. In 2021, direct tender segment dominates the primary angle-closure glaucoma market as they are the primary source of procurement of diagnostic and surgical devices by healthcare organizations and specialty clinics.
Primary Angle-Closure Glaucoma Market Country Level Analysis
The primary angle-closure glaucoma market is analysed and market size information is provided by the country, disease type, type, end user and distribution channel as referenced above.
The countries covered in Middle East and Africa primary angle-closure glaucoma market report are South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait, Rest of Middle East and Africa.
Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2020 to 2028 as Middle East and Africa counties are major developing countries and focus on increasing usage of treatment by surgical procedure and rising awareness about it. South Africa is expected to dominate in the market due to increasing prevalence of angle-closure glaucoma in the country.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increase Government Initiatives Towards Glaucoma And Recent Approval By Governing Bodies Are Creating New Opportunities In The Primary Angle-Closure Glaucoma Market
Primary angle-closure glaucoma market also provides you with detailed market analysis for every country growth in particular industry with angle-closure glaucoma surgical and diagnosis product sales, impact of advancement in the primary angle-closure glaucoma and changes in regulatory scenarios with their support for the primary angle-closure glaucoma Market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Primary Angle-Closure Glaucoma Market Share Analysis
The primary angle-closure glaucoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to primary angle-closure glaucoma market.
The major companies in primary angle-closure glaucoma market are Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.), Bausch & Lomb (a subsidiary of Bausch Health), Alcon Inc., NIDEK CO., LTD, Allergan (a subsidiary of AbbVie Inc.), BVI, Oertli Instrumente AG, Reichert Inc., among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately
Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the primary angle-closure glaucoma market.
For instance,
- In June 2020, Johnson & Johnson Vision Care, Inc. has announced to donate to Optometry Cares – The American Optometric Association (AOA) Foundation and the American Academy of Optometry Foundation. The total amount of USD 0.30 million were donated by the company for the practitioner in their support to provide eye care to the community affected by COVID-19.
Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the primary angle-closure glaucoma which also provides the benefits for organisations to improve their offerings for primary angle-closure glaucoma market.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
5 REGULATORY FRAMEWORK
6 PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA
7.1.2 INCREASING WOMEN POPULATION
7.1.3 RISE IN GERIATRIC POPULATION
7.1.4 ADVANCEMENTS IN SURGICAL TREATMENT OF THE DISEASE
7.1.5 INCREASED ECONOMIC BURDEN
7.2 RESTRAINTS
7.2.1 HIGH SURGICAL COSTS OF PACG
7.2.2 INADEQUATE REIMBURSEMENT SCENARIO
7.2.3 DELAYED AND MISDIAGNOSIS OF PACG
7.3 OPPORTUNITIES
7.3.1 INCREASING GOVERNMENT INITIATIVES TOWARDS GLAUCOMA
7.3.2 RECENT APPROVAL BY GOVERNING BODIES
7.3.3 INCREASING INCIDENCES IN EMERGING MARKET
7.3.4 RAPID TRANSITION FROM PACG MEDICATION TO SURGERIES
7.4 CHALLENGES
7.4.1 RISKS ASSOCIATED WITH SURGICAL PROCEDURES
7.4.2 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE
7.4.3 LIMITED ACCESS TO TREATMENT
8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION BY MANUFACTURERS
8.5 CONCLUSION
9 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 ACUTE ANGLE-CLOSURE GLAUCOMA MARKET
9.3 CHRONIC ANGLE-CLOSURE GLAUCOMA MARKET
10 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE
10.1 OVERVIEW
10.2 DIAGNOSIS
10.2.1 PRIMARY TEST
10.2.1.1 GONIOSCOPY EXAMINATION
10.2.1.2 SLIT-LAMP EXAMINATION
10.2.1.3 AUTOMATIC STATIC PERIMETRY
10.2.2 SECONDARY TEST
10.2.2.1 ULTRASOUND BIOMICROSCOPY
10.2.2.2 ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY (OCT)
10.2.2.3 RETINAL OCT
10.2.2.4 FUNDOSCOPY
10.2.2.5 OTHERS
10.3 TREATMENT
10.3.1 SURGICAL IRIDECTOMY
10.3.2 TRABECULECTOMY
10.3.3 MICRO INVASIVE GLAUCOMA TECHNIQUE (MIGS)
10.3.4 GONIOTOMY
10.3.5 OTHERS
11 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 AMBULATORY SURGICAL CENTERS
11.4 SPECIALTY CLINICS
11.5 OTHERS
12 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY GEOGRAPHY
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 EGYPT
13.1.3 SAUDI ARABIA
13.1.4 ISRAEL
13.1.5 UAE
13.1.6 KUWAIT
13.1.7 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT
16 COMPANY PROFILES
16.1 JOHNSON & JOHNSON VISION CARE, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 BAUSCH & LOMB INCORPORATED (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 ALCON INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 ZEISS INTERNATIONAL
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 NOVA EYE MEDICAL LIMITED
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 NIDEK CO., LTD
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 APPASAMY ASSOCIATES
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 AUROLAB
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 BVI
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 LIGHTMED
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 LUNEAU TECHNOLOGY USA
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 MEDISONIC EQUIPMENTS PVT. LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 MICROSURGICAL TECHNOLOGY
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 NEW VISION
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 NEW WORLD MEDICAL, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 OERTLI INSTRUMENTE AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 OMNI LENS
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 REICHERT, INC. (A BUSINESS UNIT OF AMETEK.INC.)
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENTS
16.2 SIGHT SCIENCES, INC.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, PIPELINE ANALYSIS
TABLE 2 NUMBER OF OPHTHALMOLOGISTS/MILLION POPULATIONS
TABLE 3 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA ACUTE-ANGLE CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA CHRONIC ANGLE-CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET,BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA HOSPITALS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA DIRECT TENDER IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA RETAIL SALES IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 31 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 32 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 33 SOUTH AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 34 SOUTH AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 35 SOUTH AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 36 SOUTH AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 37 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 40 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 41 EGYPT DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 42 EGYPT PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 43 EGYPT SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 44 EGYPT TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 45 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 47 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 48 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 49 SAUDI ARABIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 50 SAUDI ARABIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 51 SAUDI ARABIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 52 SAUDI ARABIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 53 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 56 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 57 ISRAEL DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 58 ISRAEL PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 59 ISRAEL SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 60 ISRAEL TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 61 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 64 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 65 UAE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 66 UAE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 67 UAE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 68 UAE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 69 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 72 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 73 KUWAIT DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 74 KUWAIT PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 75 KUWAIT SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 76 KUWAIT TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 77 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 79 REST OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION
FIGURE 12 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA AND ADVANCEMENT IN SURGICAL TREATMENT OF THE DISEASE ARE DRIVING THE MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 ACUTE ANGLE-CLOSURE GLAUCOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET
FIGURE 15 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020
FIGURE 16 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, CAGR (2020-2028)
FIGURE 18 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020
FIGURE 20 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2020-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020
FIGURE 24 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 28 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SNAPSHOT (2020)
FIGURE 32 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020)
FIGURE 33 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2021 & 2028)
FIGURE 34 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020 & 2028)
FIGURE 35 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY TYPE (2021-2028)
FIGURE 36 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
